Lymphatic-targeted cationic liposomes: A robust vaccine adjuvant for promoting long-term immunological memory

Vaccine

Volumn 32, Issue 42, 2014, Pages 5475-5483

  Wang, Ce ^a   Liu, Peng ^a   Zhuang, Yan ^a   Li, Ping ^a   Jiang, Boling ^a   Pan, Hong ^a   Liu, Lanlan ^a   Cai, Lintao ^a   Ma, Yifan ^a  

^a SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

Author keywords

Follicular T helper cells; Germinal center; Immunological memory; Liposome vaccine; Lymphatic targeting

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CYTOKINE; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 5; LIPOSOME; MACROGOL; MANNOSE; OVALBUMIN; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CD4 LYMPHOCYTE COUNT; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ELISA KIT; ENCAPSULATION; FEMALE; FLOW CYTOMETRY; GERMINAL CENTER; HELPER CELL; IMMUNIZATION; IMMUNOLOGICAL MEMORY; INJECTION SITE; LYMPH NODE; LYMPH VESSEL; LYMPHATIC TARGETING; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPLEEN; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL CULTURE; CHEMISTRY; IMMUNOLOGY;

ANIMALS; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; FEMALE; GERMINAL CENTER; IMMUNOLOGIC MEMORY; LIPOSOMES; LYMPH NODES; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; SPLEEN; VACCINES;

EID: 84922410221     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.081     Document Type: Article

References (34)

1. Azmi F., Ahmad Fuaad A.A., Skwarczynski M., Toth I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccines Immunother 2013, 10(3):778-796.
2. Perez O., Romeu B., Cabrera O., Gonzalez E., Batista-Duharte A., Labrada A., et al. Adjuvants are key factors for the development of future vaccines: lessons from the finlay adjuvant platform. Front Immunol 2013, 4:407.
3. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
4. Amsen D., Backer R.A., Helbig C. Decisions on the road to memory. Adv Exp Med Biol 2013, 785:107-120.
5. Christensen D., Korsholm K.S., Rosenkrands I., Lindenstrom T., Andersen P., Agger E.M. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2007, 6:785-796.
6. Henriksen-Lacey M., Christensen D., Bramwell V.W., Lindenstrom T., Agger E.M., Andersen P., et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3beta-[N-(N',N'-dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol Pharmacol 2011, 8:153-161.
7. Henriksen-Lacey M., Bramwell V.W., Christensen D., Agger E.M., Andersen P., Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 2010, 142:180-186.
8. Stills H.J. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 2005, 46:280-293.
9. Hailemichael Y., Dai Z., Jaffarzad N., Ye Y., Medina M.A., Huang X.F., et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013, 19:465-472.
10. Salerno E.P., Shea S.M., Olson W.C., Petroni G.R., Smolkin M.E., McSkimming C., et al. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother 2013, 62:1149-1159.
11. Wolf A.J., Desvignes L., Linas B., Banaiee N., Tamura T., Takatsu K., et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 2008, 205:105-115.
12. Wilson N.S., El-Sukkari D., Belz G.T., Smith C.M., Steptoe R.J., Heath W.R., et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 2003, 102:2187-2194.
13. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
14. Mamani-Matsuda M., Cosma A., Weller S., Faili A., Staib C., Garcon L., et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 2008, 111:4653-4659.
15. Fazilleau N., Eisenbraun M.D., Malherbe L., Ebright J.N., Pogue-Caley R.R., McHeyzer-Williams L.J., et al. Lymphoid reservoirs of antigen-specific memory T helper cells. Nat Immunol 2007, 8:753-761.
16. Mohanan D., Slutter B., Henriksen-Lacey M., Jiskoot W., Bouwstra J.A., Perrie Y., et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010, 147:342-349.
17. Waeckerle-Men Y., Bruffaerts N., Liang Y., Jurion F., Sander P., Kundig T.M., et al. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Vaccine 2013, 31:1057-1064.
18. Cai S., Yang Q., Bagby T.R., Forrest M.L. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011, 63:901-908.
19. Sheng K.C., Kalkanidis M., Pouniotis D.S., Esparon S., Tang C.K., Apostolopoulos V., et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol 2008, 38:424-436.
20. Kojima N., Biao L., Nakayama T., Ishii M., Ikehara Y., Tsujimura K. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. J Control Release 2008, 129:26-32.
21. Zhuang Y., Ma Y., Wang C., Hai L., Yan C., Zhang Y., et al. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution. J Control Release 2012, 159:135-142.
22. Ma Y., Zhuang Y., Xie X., Wang C., Zhou D., Wang F., et al. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale 2011, 3:2307-2314.
23. Luo Z., Li P., Deng J., Gao N., Zhang Y., Pan H., et al. Cationic polypeptide micelle-based antigen delivery system: a simple and robust adjuvant to improve vaccine efficacy. J Control Release 2013, 170:259-267.
24. Mebius R.E., Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005, 5:606-616.
25. Kaur R., Bramwell V.W., Kirby D.J., Perrie Y. Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response. J Control Release 2012, 164:331-337.
26. Crotty S., Ahmed R. Immunological memory in humans. Semin Immunol 2004, 16:7.
27. Taylor J.J., Pape K.A., Jenkins M.K. A germinal center-independent pathway generates unswitched memory B cells early in the primary response. J Exp Med 2012, 209:597-606.
28. Pape K.A., Kouskoff V., Nemazee D., Tang H.L., Cyster J.G., Tze L.E., et al. Visualization of the genesis and fate of isotype-switched B cells during a primary immune response. J Exp Med 2003, 197:1677-1687.
29. McHeyzer-Williams M., Okitsu S., Wang N., McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol 2012, 12:24-34.
30. Baumjohann D., Preite S., Reboldi A., Ronchi F., Ansel K.M., Lanzavecchia A., et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 2013, 38:596-605.
31. Bachmann M.F., Odermatt B., Hengartner H., Zinkernagel R.M. Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med 1996, 183:2259-2269.
32. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Ann Rev Immunol 2004, 22:745-763.
33. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999, 163:6448-6454.
34. Purkerson J., Isakson P. A two-signal model for regulation of immunoglobulin isotype switching. FASEB J 1992, 6:3245-3252.